Evidence map›Paper›PMID 42429629›Full record

ArticleJournal of virology2026

HIV superinfection reveals sequential reservoir reactivation and immune-driven rebound dynamics.

F Harrison Omondi, Aniqa Shahid, Natalie N Kinloch, Winnie Dong, Maggie C Duncan, Fatima Yaseen, Evan Barad, Nadia Moran-Garcia, Amanda Cabral da Silva, Vitaliy Mysak and 8 more

Abstract read
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

F Harrison OmondiFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.ORCID 0000-0003-0940-7512
Aniqa ShahidFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Natalie N KinlochFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Winnie DongBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Maggie C DuncanFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Fatima YaseenBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Evan BaradFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Nadia Moran-GarciaBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Amanda Cabral da SilvaFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.ORCID 0000-0003-1868-7579
Vitaliy MysakBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Don KirkbyBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Mario OstrowskiDepartment of Immunology, University of Toronto, Toronto, Canada.ORCID 0000-0002-7369-1936
Rebecca M LynchDepartment of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, DC, USA.
Chanson J BrummeBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Colin KovacsMaple Leaf Clinic, Toronto, Canada.
R Brad JonesInfectious Disease Division, Department of Medicine, Weill Cornell Medical College, New York, New York, USA.ORCID 0000-0003-4470-1231
Guinevere Q LeeInfectious Disease Division, Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
Zabrina L BrummeFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.ORCID 0000-0002-8157-1037

Funding

REACH: Research Enterprise to Advance a Cure for HIVUM1AI164565 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Marina Caskey, R. Brad Jones · 2021 to 2026
$32.9M
Canadian HIV Cure Enterprise (CanCURE) BR4-197730CIHR HB1-164063CIHR PJT-159625Martin Delaney "REACH" Collaboratory NIH grant 1-UM1AI164565-01NIAID NIH HHS UM1 AI164565sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative DEL-15-006Wellcome Trust
6 · The paper itself

Abstract

Superinfection, where a person with HIV acquires a second phylogenetically distinct strain, provides an opportunity to study reservoir evolutionary dynamics because the two strains can be tracked over time. We hereby characterize such a case that originally went undetected by clinical monitoring. The participant, who expressed the protective HLA-B*57:03 allele, initially controlled his subtype B infection but lost control after superinfection with a unique recombinant form (URF), which came to dominate in plasma without displacing the original B strain. Five years after initiating therapy, replication-competent proviruses from both strains persisted in blood, though URF proviruses dominated (80%). Despite their unequal representation within the reservoir, both strains rapidly rebounded upon treatment interruption, though most rebounding sequences belonged to a URF subclade that predated ART initiation. During the treatment interruption, genetically distinct viral lineages continually appeared in plasma, consistent with sequential "waves" of reactivation of diverse reservoir clones. Notably, immune escape variants emerged from the reservoir in a later "wave," displacing initial susceptible variants and underscoring the important role of immune responses in shaping rebound dynamics. Sequence analysis revealed that the URF transmitted/founder virus already harbored key HLA-B*57:03-associated escape mutations, likely explaining the loss of viral control after superinfection. Our results reveal that superinfection can remain undetected despite routine HIV clinical monitoring, pre-adaptation of the superinfecting strain to host HLA can undermine immune control, immune-escaped virus can re-emerge from reservoirs during treatment interruption, and immune responses can actively shape viral rebound dynamics.IMPORTANCEThis case demonstrates that HIV superinfection can go undetected by routine clinical monitoring, underscoring the importance of assays that capture HIV diversity-particularly those used to screen participants for cure trials. It also illustrates how pre-adaptation of a superinfecting strain to host HLA-restricted immune responses can evade existing immunity, with implications for understanding natural immune control, and underscoring the challenge of viral diversity for vaccine and immunotherapy design. The sequential emergence of genetically diverse HIV lineages during treatment interruption, including minority immune-escape variants that emerge from the reservoir to displace the initial susceptible population, highlights the difficulty of predicting rebound viral composition and underscores the key role of immune responses in shaping rebound dynamics. Critically, escaped rebound variants can then reseed the reservoir, thereby enriching it in escaped forms, highlighting a specific vulnerability for cure approaches that harness natural immune responses to eliminate reservoir cells.

Indexed as

HIV-1HIV InfectionsSuperinfectionVirus ActivationHLA-B AntigensHumansImmune EvasionMalePhylogenyProvirusesViral LoadHLA-B AntigensHIV reservoirHIV superinfectionimmune escaperebound dynamics

Identifiers

PMID42429629
PMCPMC13483397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.